Digital Respiratory Devices Market

• Increasing prevalence of respiratory disorders, such as COPD, TB, asthma, and sleep apnea is driving the market growth

The considerable rise in the prevalence of severe chronic respiratory diseases (CRDs) like bronchial asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, lung disorders, and pulmonary hypertension (PH) is responsible for the market growth. A growing senior population, tobacco usage, increased air pollution, and occupational exposure to dust in the mining, forestry, and agricultural industries all contribute to a steadily rising risk of acquiring CRDs. As a result, the market for respiratory management tools is expanding quickly. Clinical testing, regulatory processes, and post-approval operations have become more difficult as a result of the COVID-19 pandemic.

This is primarily due to challenges with patient enrollment, treatment, and recruitment for clinical research.

However, it is projected that the use of smart inhalers will rise in the post-pandemic era as healthcare providers resort to linked medical devices to guarantee that patients receive the best care and advice available, regardless of the situation. This is due to the fact that many patients suffered since they were unable to receive consultations and treatments in person due to the pandemic's restrictions. 

The pandemic illustrated just how deadly respiratory infections and diseases can become if not promptly and adequately managed. According to the research that is currently available, digital inhalers help asthma and COPD patients better manage their medications and receive direct clinical care. The benefits of improved medication adherence have the potential to improve clinical outcomes and reduce the need for more expensive or complex therapies like biologics.

Additionally, positive results were seen with the usage of Adherium's smart inhaler system in a 12-month controlled research that was carried out in January 2017 at the Sheffield Children's Hospital in the United Kingdom. Less hospitalizations, better medication adherence, and fewer doctor visits were some of the beneficial medical outcomes. The global market is being driven by an increasing number of key developments in digital respiratory technology. For instance, FindAir medical's FindAir ONE smart inhaler device, which has received CE certification, is available to the general public in Europe as of January 2019. 

To increase the effectiveness of drug management, an increasing number of enterprises are adding digital technologies into their products. For instance, HeroTracker Sense was introduced by Aptar Pharma in April 2022. A standard metered dosage inhaler (pMDI) is transformed into a smart linked healthcare device by this revolutionary digital respiratory health solution. Thus, driving the Digital Respiratory Devices market revenue.

Growing awareness and education regarding respiratory health are vital factors influencing the Global Digital Respiratory Devices Market Industry. Public health campaigns aimed at educating individuals about respiratory diseases and their management are becoming more prevalent. These initiatives encourage patients to utilize digital respiratory devices for better disease management and adherence to treatment plans. As patients become more informed about their conditions, the demand for innovative solutions is expected to rise. This heightened awareness is anticipated to contribute to the market's growth trajectory, aligning with the increasing focus on preventive healthcare.

Government initiatives and support for digital health innovations are crucial drivers of the Global Digital Respiratory Devices Market Industry. Many countries are implementing policies that promote the adoption of digital health technologies to improve healthcare delivery and patient outcomes. For example, funding programs and grants are being established to support research and development in digital respiratory devices. Additionally, regulatory bodies are streamlining approval processes for new technologies, facilitating quicker market entry. This supportive environment is likely to foster innovation and growth within the industry, contributing to its overall expansion.

The Global Digital Respiratory Devices Market Industry experiences a notable surge due to the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). According to health organizations, respiratory diseases are among the leading causes of morbidity and mortality worldwide. The World Health Organization indicates that millions of individuals are affected, necessitating effective management solutions. Digital respiratory devices, including smart inhalers and monitoring systems, are becoming essential tools for patients and healthcare providers alike. This trend is expected to drive the market's growth, contributing to its valuation of 57.5 USD Billion in 2024.

The Global Digital Respiratory Devices Market Industry is significantly influenced by the growing emphasis on remote patient monitoring. Healthcare systems worldwide are increasingly adopting telehealth solutions to manage chronic diseases, including respiratory conditions. Remote monitoring devices enable healthcare professionals to track patients' respiratory health from afar, ensuring timely interventions and reducing hospital visits. This trend is particularly beneficial for patients in rural or underserved areas. The market is projected to grow at a compound annual growth rate of 25.5% from 2025 to 2035, reflecting the rising demand for innovative solutions that enhance patient care and accessibility.

Technological advancements play a pivotal role in the expansion of the Global Digital Respiratory Devices Market Industry. Innovations in artificial intelligence, machine learning, and mobile health applications enhance the functionality and efficacy of respiratory devices. These technologies facilitate real-time monitoring and data analysis, allowing for personalized treatment plans. For instance, devices equipped with AI algorithms can predict exacerbations in patients with chronic respiratory conditions, thereby improving outcomes. As these technologies continue to evolve, they are likely to attract investments and drive market growth, potentially reaching a valuation of 699.3 USD Billion by 2035.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Digital Respiratory Devices Market dominated this market in 2022 (45.80%). Asthma, COPD, and other chronic respiratory disorders are becoming more prevalent, which is the cause of this. More than 25 million Americans suffer with asthma. 

Additionally, 14.8 million individuals in the United States have COPD, and the disease claims the lives of 150,000 Americans each year, or one every four minutes. Further, the U.S. market of Digital Respiratory Devices held the largest market share, and the Canada market of Digital Respiratory Devices was the fastest growing market in the North America region.Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: DIGITAL RESPIRATORY DEVICES MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Digital Respiratory Devices market accounted for the healthy market share in 2022. During the projection period, it is anticipated that significant advancements in digital respiratory products and their rising acceptance and accuracy will drive market expansion. Further, the German market of Digital Respiratory Devices held the largest market share, and the U.K market of Digital Respiratory Devices was the fastest growing market in the European region

The Asia Pacific Digital Respiratory Devices market is expected to register significant growth from 2023 to 2032. Growing COPD and asthma incidence rates in China and India are mainly blame for this expansion. The number one cause of impairment in China is COPD, which is also a significant public health concern. AstraZeneca's Bevespi Aerosphere, which is used to treat COPD symptoms such chronic bronchitis and/or emphysema, obtained approval in China in May 2020.

Moreover, China’s market of Digital Respiratory Devices held the largest market share and the Indian market of Digital Respiratory Devices was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the market of Digital Respiratory Devices, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Digital Respiratory Devices industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Digital Respiratory Devices industry to benefit clients and increase the market sector. In recent years, the Digital Respiratory Devices industry has offered some of the most significant advantages to medicine. 

Major players in the Digital Respiratory Devices market, including COHERO Health Inc, Cognita Labs, Adherium Limited, Amiko Digital Health Limited, Teva Pharmaceuticals Industries Ltd., Propeller Health, Novartis AG, Pneuma Respiratory Inc., 3M Health Care Limited, AireHealth, Inc., and FindAir Sp. z o.o, are attempting to increase market demand by investing in research and development Products.

A healthcare firm called Novartis AG (Novartis) specializes in the development, production, and marketing of prescription and over-the-counter medicines, as well as products for eye care. In addition to others, it offers medicines for the treatment of solid tumors, immunological disorders, infections, cardiovascular illness, dermatological issues, neurological disorders, ophthalmic and respiratory diseases, cancer, and neurological disorders. 

Through Sandoz, the business provides biosimilars and generic medications. Through the Novartis Institutes for BioMedical Research (NIBR), Novartis carries out research in a number of disease-related fields. In the Americas, Europe, the Middle East, Africa, and Asia-Pacific, the corporation has a network of subsidiaries and offices. Basel, Switzerland serves as the headquarters of Novartis.

AstraZeneca Plc (AstraZeneca) is a biopharmaceutical firm that focuses on the development, manufacturing, and marketing of a variety of prescription medications. It creates goods for the treatment of ailments like cancer, autoimmune, infectious, neurological, and respiratory, cardiovascular, renal, and metabolic problems. Vaccines, prescription medications, and biologics are all part of the company's product line. Through distributors, local representative offices, and wholly-owned local marketing firms, AstraZeneca offers its products. 

The business sells its goods to general practitioners and specialists in medicine. Operating regions for the corporation include Europe, the Americas, Asia, Africa, and Australasia. The U.K.'s Cambridge, in Cambridgeshire, serves as the company's headquarters. AstraZeneca's Bevespi Aerosphere, which is used to treat COPD symptoms such chronic bronchitis and/or emphysema, obtained approval in China in May 2020.